Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Epax Norway AS is currently managing 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are handled by 2 distinct examiners, meaning that each application is being reviewed by a different official. The prosecution activity is spread across 2 distinct art units, indicating that both of the 2 pending office actions are being evaluated by different technical groups within the patent office.
The busiest examiner, KUCKLA, ANNA GRACE, is managing 1 busiest examiner pending action. This reflects the even distribution of the 2 pending office actions between the 2 distinct examiners. There is no concentration of work with any single individual, and each matter is proceeding through a different art unit, which requires a versatile approach to prosecution strategy.
For practitioners, the presence of 2 distinct examiners and 2 distinct art units means that each of the 2 pending office actions requires an independent response plan. There is no overlap in the examination teams, so each case must be managed on its own merits without leveraging prior interactions with the same examiner. The 1 busiest examiner pending action with KUCKLA, ANNA GRACE represents one of the two active prosecution paths for the company.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (50%) |
| §103 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KUCKLA, ANNA GRACE | 1 | 53.2% | +54.1% |
| WHITE, DAWANNA SHAR-DAY | 1 | 62.5% | +23.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17311600 | VERY LONG CHAIN FATTY ACID COMPOSITIONS | WHITE, DAWANNA SHAR-DAY | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19329060 | VERY LONG CHAIN FATTY ACIDS FOR TREATMENT AND ALLEVIATION OF DISEASES | KUCKLA, ANNA GRACE | 23d |
| 17311600 | VERY LONG CHAIN FATTY ACID COMPOSITIONS | WHITE, DAWANNA SHAR-DAY | — |
| Art Unit | Apps |
|---|---|
| 1626 | 1 |
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19329060 | VERY LONG CHAIN FATTY ACIDS FOR TREATMENT AND ALLEVIATION OF DISEASES | KUCKLA, ANNA GRACE | 1626 | §103 | Final Rejection | 23d | Pending | Sep 15, 2025 |
| 17311600 | VERY LONG CHAIN FATTY ACID COMPOSITIONS | WHITE, DAWANNA SHAR-DAY | 1627 | §101 | Final Rejection | — | Pending | Jun 07, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial